Transcode Therapeutics, Inc.

General Information
Business:

TransCode Therapeutics is an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. We have created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Our drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively.

(Note: TransCode Therapeutics priced its IPO on July 8, 2021, in line with the terms in its amended prospectus: 6.25 million shares at $4 to raise $25 million. On May 3, 2021, TransCode Therapeutics cut its IPO price to $4, down from a range of $8 to $10, and raised the number of shares to 6.3 million, up from 2.8 million, according to an S-1/A filing. The estimated IPO proceeds are the same – $25.2 million – but the market valuation, based on mid-point pricing, was cut by 37 percent to about $48 million on the current terms, down from $76.41 million previously.)

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 6
Founded: 2016
Contact Information
Address 6 Liberty Square, #2382 Boston, MA 02109
Phone Number (857) 837-3099
Web Address http://www.transcodetherapeutics.com
View Prospectus: Transcode Therapeutics, Inc.
Financial Information
Market Cap $47.88mil
Revenues $0 mil (last 12 months)
Net Income $-2.34 mil (last 12 months)
IPO Profile
Symbol RNAZ
Exchange NASDAQ
Shares (millions): 6.3
Price range $4.00 - $4.00
Est. $ Volume $25.0 mil
Manager / Joint Managers ThinkEquity (a division of Fordham Financial Management)
CO-Managers -
Expected To Trade: 7/9/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change